摘要
目的 探讨依托泊苷联合奥沙利铂治疗非小细胞肺癌(NSCLC)的临床效果。方法 选取2019年5月至2021年4月我院收治的80例NSCLC患者,按照抽签法分为观察组与对照组。对照组采用放疗治疗,观察组在对照组基础上采用依托泊苷联合奥沙利铂治疗。比较两组的治疗效果、生存时间、不良反应。结果 观察组治疗总有效率为52.00%,高于对照组的25.00%(P <0.05)。观察组中位生存时间长于对照组(P <0.05)。观察组骨髓抑制及粒细胞减少发生率分别为30.00%、 25.00%,高于对照组的10.00%、 7.50%(P <0.05)。结论 依托泊苷联合奥利沙铂同步放疗治疗NSCLC的效果理想,可延长患者的生存时间,但不良反应发生率相对较高。
Objective To explore the clinical effect of etoposide combined with oxaliplatin in the treatment of non-small cell lung cancer(NSCLC).Methods 80 NSCLC patients admitted to our hospital from May 2019 to April 2021 were selected and divided into observation group and control group according to lottery method.The control group was treated with radiotherapy,and the observation group was treated with etoposide and oxaliplatin on the basis of the control group.The treatment effect,survival time and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 52.00%,higher than 25.00%in the control group(P<0.05).The median survival time of observation group was longer than that of control group(P<0.05).The incidences of myelosuppression and granulocytopenia in the observation group were 30.00%and 25.00%,respectively,higher than 10.00% and 7.50% in the control group(P<0.05).Conclusions Etoposide combined with oxaliplatin and radiotherapy has ideal effect in the treatment of NSCLC,which can prolong the survival time of patients,but the incidence of adverse reactions are relatively high.
作者
姚赛
田永京
YAO Sai;TIAN Yongjing(Department of Western Medicine,Nanyang Oncology Hospital,Nanyang 473000,China;Department of Thoracic Surgery,Nanyang Oncology Hospital,Nanyang 473000,China)
出处
《临床医学工程》
2024年第3期325-326,共2页
Clinical Medicine & Engineering
